Core Viewpoint - The company expects a significant revenue increase of approximately 110% to 120% for the fiscal year ending December 31, 2025, compared to the fiscal year ending December 31, 2024, primarily driven by breakthroughs in the commercialization of its core product, the Tumi surgical robot [1] Group 1: Revenue Growth - The rapid sales growth is attributed to the successful expansion of the Tumi surgical robot in overseas markets, with over 100 new orders signed in these markets throughout the year [1] - Overseas market sales revenue has increased to more than five times that of the previous year, significantly outpacing the industry average growth rate, indicating strong global expansion momentum [1] Group 2: Order and Installation Metrics - As of the announcement date, the total commercialized orders for the Tumi robot globally have exceeded 180 units, with the cumulative installed base surpassing 120 units [1] Group 3: Financial Performance - The company anticipates an adjusted net loss of no more than RMB 240 million for the fiscal year ending December 31, 2025, which represents a reduction of over 50% compared to the adjusted net loss of approximately RMB 482 million for the fiscal year ending December 31, 2024 [1] - This reduction in loss is primarily due to rapid revenue growth and significant decreases in product costs and operating expenses through various cost-control measures [1] - The company expects a substantial narrowing of free cash flow net outflow by over 80% for the fiscal year ending December 31, 2025, to no more than RMB 70 million compared to the previous fiscal year [1]